Aura Biosciences (NASDAQ:AURA) Posts Earnings Results, Misses Expectations By $0.09 EPS

Aura Biosciences (NASDAQ:AURA) posted its quarterly earnings results on Monday. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.09), Zacks reports.

Aura Biosciences Stock Performance

Shares of NASDAQ:AURA opened at $7.00 on Tuesday. The company’s fifty day moving average is $7.65 and its two-hundred day moving average is $8.66. Aura Biosciences has a 1-year low of $6.33 and a 1-year high of $12.38. The stock has a market capitalization of $349.66 million, a price-to-earnings ratio of -4.05 and a beta of 0.30.

Insider Activity

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders sold 23,045 shares of company stock valued at $177,242. Company insiders own 5.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a report on Monday. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Aura Biosciences presently has a consensus rating of “Buy” and an average target price of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.